Efficacy of Monoclonal Antibodies Against Calcitonin Gene-Related Peptide for Medication Overuse Headache in Migraine Patients: Literature Review

Medication overuse headache (MOH) is a type of headache that is caused by an excessive use of pain-relief medication, most commonly in individuals with migraine. This condition negatively impacts the quality of life of those affected, while also placing a significant socioeconomic burden on the hea...

Full description

Saved in:
Bibliographic Details
Main Authors: A. Kairytė, P. Lukoševičius, G. Žemgulytė
Format: Article
Language:English
Published: Vilnius University Press 2024-12-01
Series:Neurologijos seminarai
Subjects:
Online Access:https://ojs.test/index.php/neurologijos_seminarai/article/view/38296
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Medication overuse headache (MOH) is a type of headache that is caused by an excessive use of pain-relief medication, most commonly in individuals with migraine. This condition negatively impacts the quality of life of those affected, while also placing a significant socioeconomic burden on the healthcare system. Over the past decade, preventive treatment has become a lot more prominent in the management of MOH in an attempt to reduce the risk of medication overuse. Although medication groups such as antidepressants, beta-blockers, and antiepileptics are still being used for preventive treatment, more recent and specific treatments, namely, monoclonal antibodies against calcitonin gene-related peptide (CGRP), are being increasingly applied. This review article discusses the epidemiology and risk factors of MOH as well as the latest clinical studies investigating the efficacy of monoclonal antibodies against CGRP in treating MOH in patients suffering from migraine.
ISSN:1392-3064
2424-5917